1) 2014 Sales of Therapeutic Antibodies
- Anti-TNF Antibody Sales 2014
- Cancer Antibody Sales 2014
- Other Anti-Inflammatory Antibody Sales 2014
- Ophthalmic Antibody Sales 2014
- Cardiometabolic & Antiviral Antibody Sales 2014
2) VEGF Antibodies
Marketed VEGF & VEGF-R Antibodies in Oncology:
- Avastin Sales & Pipeline
- Zaltrap Sales & Pipeline
- Cyramza Sales & Pipeline
Avastin & Zaltrap Biosuperiors:
- Anti-VEGF & Antibody Combination Pipeline
- Bispecific Anti-VEGF Antibody Pipeline
Cyramza Biosuperiors:
- Anti-VEGF-R & Antibody Combination Pipeline
- Bispecific Anti-VEGF-R Antibody Pipeline
Avastin Biosimilar Pipeline:
Marketed VEGF Antibodies in Ophthalmology:
- Lucentis Sales & Pipeline
- Eylea Sales & Pipeline
Biosuperior Lucentis & Eylea Pipeline:
- Anti-VEGF Pipeline in Ophthalmology
- Bispecific Anti-VEGF and Antibody Combination Pipeline in Ophthalmology
Lucentis Biosimilar Pipeline
3) TNF Antibodies
Tab. 1: Approved and marketed indications of anti-TNF antibodies in regulated markets
Tab. 2: Additional indications of branded anti-TNF antibodies under development
Tab. 3: 2014 Sales of anti-TNF Antibodies
Marketed TNF Antibodies
Humira Sales & Pipeline
Remicade Sales & Pipeline
Enbrel Sales & Pipeline
Simponi Sales & Pipeline
Cimzia Sales & Pipeline
Biosuperior / Biobetter TNF Antibodies
Biosimilar TNF Antibodies
Humira Biosimilar Antibody Pipeline
Remicade Biosimilar Antibody Pipeline
Enbrel Biosimilar Antibody Pipeline
Cimzia Biosimilar Antibody Pipeline
4) Her2 Antibodies
Marketed Her2 Antibodies
Herceptin Sales & Pipeline
Perjeta Sales & Pipeline
Kadcyla Sales & Pipeline
Trastuzumab Biosuperiors
Engineered Her2 Antibodies
Bi- and Multispecific Her2 Antibodies
Her2 Antibody-Drug Conjugates
Other Her2 Antibodies
Herceptin Biosimilars
5) CD20 Antibodies
2014 Sales of CD20 Antibodies
Marketed CD20 Antibodies & Sales
Rituxan/MabThera Pipeline & Sales
Gazyva/ Gazyvaro Pipeline & Sales
Arzerra Pipeline & Sales
Zevalin Pipeline & Sales
Biosuperior CD20 Antibodies
Biosimilar CD20 Antibodies
Rituxan/MabThera (rituximab) Biosimilars
6) EGF-R Antibodies
2014 Sales of EGF-R Antibodies
Marketed EGF-R Antibodies
Erbitux Sales & Pipeline
Vectibix Sales & Pipeline
Nimotuzumab Pipeline
EGF-R Antibody Biosuperiors
Engineered EGF-R Antibodies
Bi- and Multispecific EGF-R Antibodies
EGF-R Antibody-Drug Conjugates
EGF-R Antibody Biosimilars
Cetuximab Biosimilars
7) RANKL Antibodies
Marketed RANKL Antibodies
Prolia Sales & Pipeline
XGEVA Sales & Pipeline
Ranmark/Pralia Pipeline
Biosuperior RANKL Antibodies
Biosimilar RANKL Antibodies
8) Complement C5 Antibodies
Marketed C5 Antibody Sales & Pipeline
Biosuperior C5 Antibodies
Biosimilar C5 Antibodies
9) Interleukin-12/-23 Antibodies
Marketed IL-12/-23 Antibody Sales & Pipeline
10) Alpha4/Beta1/7 Antibodies
Marketed alpha4/beta1/7 Antibody Sales & Pipeline
11) IgE Antibodies
Marketed IgE Antibody Sales & Pipeline
Biosuperior IgE Antibodies
Biosimilar IgE Antibodies
12) CD80/86 (B7-1/B7-2) Antibodies
Marketed CD80/86 Antibodies Sales & Pipeline
Biosuperior CD80/86 Antibodies
Biosimilar CD80/86 Antibodies
13) Interleukin-6 Receptor (IL-6R) Antibodies
Marketed IL-6R Antibody Sales & Pipeline
Biosuperior IL-6R Antibodies
Biosimilar IL-6R Antibodies
14) Respiratory Syncytial Virus (RSV) Antibodies
Marketed RSV Antibody Sales
Biosuperior RSV Antibodies
Biosimilar RSV Antibodies
15) CD52 Antibodies
Marketed CD52 Antibody Sales
Biosuperor CD52 Antibodies
Biosimilar CD52 Antibodies
Corporate Therapeutic Antibody Biosimilar & Biosuperior Pipelines